KR900015721A - 신규 방법 및 화합물들 - Google Patents

신규 방법 및 화합물들 Download PDF

Info

Publication number
KR900015721A
KR900015721A KR1019900004922A KR900004922A KR900015721A KR 900015721 A KR900015721 A KR 900015721A KR 1019900004922 A KR1019900004922 A KR 1019900004922A KR 900004922 A KR900004922 A KR 900004922A KR 900015721 A KR900015721 A KR 900015721A
Authority
KR
South Korea
Prior art keywords
compound
formula
group
cyanophenyl
salt
Prior art date
Application number
KR1019900004922A
Other languages
English (en)
Inventor
모리스 에번즈 존
스템프 제프리
스튜어트 하들리 마이클
버릴 고오든
Original Assignee
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비이참 그루우프 피이엘시이 filed Critical 비이참 그루우프 피이엘시이
Publication of KR900015721A publication Critical patent/KR900015721A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/10—Inorganic compounds or compositions
    • C30B29/40—AIIIBV compounds wherein A is B, Al, Ga, In or Tl and B is N, P, As, Sb or Bi
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/60—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Metallurgy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Materials Engineering (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Manufacturing & Machinery (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음.

Description

신규 방법 및 화합물들
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 비-독성적이고 제약학적으로 허용가능한 량의 하기 일반식(I) 화합물 또는 이들의 제약학적으로 허용가능한 염 또는 이들의 제약학적으로 허용가능한 이들의 용매 화합물로 구성된 호흡 시스템질환의 치료 및/또는 심장혈관 질환 및/또는 신경 단위 변성 질환의 치료용 제약학적 조성물.
    상기식에서 R1은 CN, NO2, CF3할로겐, C2-12알킬 및 C2-12알킬카르보닐로 구성된 군으로 부터 선택된 3개까지의 치환체로 치환된 아릴기이며 ; R2는 s 또는 NCN이며; R3알킬기 또는 아릴기이다.
  2. R1이 CN, NO2, CF3할로겐, C2-12알킬 및 C2-12알킬카르보닐로 구성된 군으로 부터 선택된 3개까지의 치환체로 치환된 아릴기이며 ; R2는 s 또는 NCN이며; R3알킬기 또는 아릴기이며 단, R1이 4-3차 부틸 페닐이고 R3이 페닐일 때 R2는 NCN이며 R1이 3- 또는 4-시아노페닐이고 R3이 1,2,2-트리메틸프로필이거나 R1이 2,6-디클로로페닐이며 R3이 3차 부틸일때 R2가 s인 것을 특징으로 하는 하기 일반식(IA) 화합물, 또는 이들의 염 또는 이들의 용매화합물.
  3. 제2항에 있어서 R2s인 화합물.
  4. 제2항 또는 제3항에 있어서 R1이 일치환된 화합물.
  5. 제2항 내지 제4항중 어느 한 항에 있어서, R1이 3-시아노페닐, 4-시아노페닐, 3-플루오로페닐 또는 4-플루오로페닐인 화합물.
  6. 제2항 내지 제5항중 어느 한 항에 있어서 R3이 분지된 C4-6또는 분지된 C5-9알킬기인 화합물.
  7. 제2항 내지 제6항중 어느 한 항에 있어서, R3이 삼차부릴 또는 1,2,2-트리메틸프로필 기인 화합물.
  8. 제2항에 있어서 하기 일반식(IB)의 화합물;
    상기 식에서 R1은 CN, NO2, CF3할로겐, C2-12알킬 및 C2-12알킬카르보닐기로 일치환된 페닐이고; R2는 s 또는 NCN이며; R3는 c1-9알킬기 또는 페닐이며, 단 R1이 4-삼차. 부틸-페닐이고 R3가 페닐일때, R2가 NCN이며 R1이 3- 또는 4-시아노페닐이고 R3는 1,2,2-트리메틸프로필이거나, R1이 2,6-티클로로페닐이고 R3가 삼차부틸을 나타낼때, R2는 s이다.
  9. 제2항에 있어서, (±)-N-4-시나노페닐-N'-1,2,2-트리메틸프로프-1-일티오우레아, (±)-N-3-시아노페닐-N'-1,2,2-트리메틸프로프-1-일티오우레아, (±)-N-4-플루오로페닐-N'-1,2,2-트리메틸프로프-1-일티오우레아, (±)-N"-3-사아노-N-4-루오노페닐-1,2,2-트리메틸프로프-1-일루아니딘; 및 N-4-시아노페닐-N'-t-부틸티오우레아; 또는 그 염 또는 그 용매 화합물로 이루어진 군으로 부터 선택된 화합물.
  10. 제2항에 있어서, (±)-N-4-시나노페닐-N'-1,2,2-트리메틸프로프-1-일티오우레아; 또는 그염 또는 그 용매 화합물인 화합물.
  11. a) R2가 s인 일반식(IA)의 화합물을 위해서는 일반식(II)
    의 화합물을 일반식(III)
    의 화합물과 반응시켜 일반식
    의 화합물을 형성하거나 b) R2가 SCN인 일반식(IA)의 화합물을 위해서는, 일반식(IV)
    의 화합물을 시아나미드와 반응시켜, 일반식(ID)
    의 화합물을 형성한 후에(상기 식들에게 R1' R3'는 각각 R1및 R3이거나 이것으로 전환가능한 기임), 필요한 경우 i) R1' 또는 R3'를 R1및 R3로 각각 전환시키고; ii) 일반식(I)의 화합물의 염을 제조하고; iii) 일반식(I)의 화합물의 용매 화합물 또는 그 염을 제조하는 하 이상의 임의 단계들로 수행되는 것으로 구성되는 방법을 특징으로 하는 일반식(IA)의 화합물의 제조 방법.
  12. 활성적인 치료학적 물질로서 사용하기 위한, 일반식(IA), 또는 그들의 제약학적으로 허용가능한 염, 또는 계약학적으로 허용가능한 용매 화합물.
  13. 치료학적으로 유효량의 일반식(IA)의 화합물, 또는 그들의 제약학적으로 허용가능한 염, 또는 계약학적으로 허용가능한 용매 화합물, 및 제약학적으로 허용가능한 담체로 구성되는 제약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900004922A 1989-04-11 1990-04-10 신규 방법 및 화합물들 KR900015721A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB89080634 1989-04-11
GB898908063A GB8908063D0 (en) 1989-04-11 1989-04-11 Novel compounds

Publications (1)

Publication Number Publication Date
KR900015721A true KR900015721A (ko) 1990-11-10

Family

ID=10654760

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900004922A KR900015721A (ko) 1989-04-11 1990-04-10 신규 방법 및 화합물들

Country Status (9)

Country Link
EP (1) EP0392802A3 (ko)
JP (1) JPH02290841A (ko)
KR (1) KR900015721A (ko)
AU (1) AU619968B2 (ko)
CA (1) CA2014196A1 (ko)
GB (1) GB8908063D0 (ko)
NZ (1) NZ233252A (ko)
PT (1) PT93717A (ko)
ZA (1) ZA902707B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504278A (ja) * 1944-06-01 1997-04-28 ザ、ウェルカム、ファンデーション、リミテッド Ｎｏシンターゼインヒビターとしての置換尿素およびイソチオ尿素誘導体
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US5278169A (en) * 1988-08-09 1994-01-11 E. R. Squibb & Sons, Inc. Method of treating or prevention of fibrillation of the heart
JPH0395153A (ja) * 1989-06-15 1991-04-19 Mitsubishi Kasei Corp ジフェニル尿素誘導体
JP2749639B2 (ja) * 1989-06-28 1998-05-13 鐘紡株式会社 シアノグアニジン誘導体
WO1992011233A1 (en) * 1990-12-19 1992-07-09 Kanebo, Ltd. Arylcyanoguanidine derivative, production thereof, and potassium channel opening agent containing the same as active ingredient
US5371086A (en) * 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
JPH05294935A (ja) * 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
FR2677019B1 (fr) * 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
HUT62558A (en) * 1991-07-01 1993-05-28 Sandoz Ag Process for producing n-phenylthiourea derivaties and pharmaceutical compositions comprising same
IL102548A (en) * 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
US5593993A (en) * 1991-08-02 1997-01-14 Medivir Ab Method for inhibition of HIV related viruses
US6225305B1 (en) 1993-10-04 2001-05-01 Glaxo Wellcome Inc. Substituted urea and isothiorea derivatives as no synthase inhibitors
US6090846A (en) * 1994-06-01 2000-07-18 Glaxo Wellcome Inc. Substituted urea and isothiourea derivatives as no synthase inhibitors
US6297276B1 (en) 1993-10-04 2001-10-02 Glaxosmithkline Substituted urea and isothiourea derivatives as no synthase inhibitors
GB9418912D0 (en) * 1994-09-20 1994-11-09 Fisons Corp Pharmaceutically active compounds
TW397812B (en) * 1995-02-11 2000-07-11 Astra Ab Bicyclic isothiourea derivatives useful in therapy
EP0939634A4 (en) * 1996-08-15 2001-02-21 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6013668A (en) 1997-08-13 2000-01-11 Bristol-Myers Squibb Company Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile
US6458835B2 (en) 1997-08-13 2002-10-01 Bristol-Myers Squibb Company Method of inhibiting or treating chemotherapy-induced hair loss
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
KR20040094687A (ko) * 2002-02-13 2004-11-10 비트레오-레티날 테크놀로지스, 인크. 우레아 및 우레아 유도체를 이용한 안질환의 치료

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2702235A1 (de) * 1977-01-20 1978-07-27 Bayer Ag Neue n-aryl-n'-alkyl-thioharnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung als mittel zur bekaempfung von tierischen und pflanzlichen schaedlingen

Also Published As

Publication number Publication date
CA2014196A1 (en) 1990-10-11
ZA902707B (en) 1991-06-26
AU5302490A (en) 1990-10-18
GB8908063D0 (en) 1989-05-24
NZ233252A (en) 1993-02-25
EP0392802A2 (en) 1990-10-17
AU619968B2 (en) 1992-02-06
EP0392802A3 (en) 1992-06-03
JPH02290841A (ja) 1990-11-30
PT93717A (pt) 1990-11-20

Similar Documents

Publication Publication Date Title
KR900015721A (ko) 신규 방법 및 화합물들
KR920021523A (ko) 신규한 우레아 유도체, 이의 제조 방법 및 이들을 함유하는 약제학적 조성물
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
ES8304994A1 (es) &#34;procedimiento para preparar nuevos compuestos de cefem&#34;.
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
KR890011902A (ko) 디데옥시디데히드로카르보시클릭 뉴클레오시드
RU95115522A (ru) Соединение, пригодные для лечения заболеваний цнс, фармацевтическая композиция
EP0277384A3 (en) 1h-imidazole-5-carboxylic acid derivatives
EP0096569A3 (en) Triazole antifungal agents
EP0051061A3 (en) Novel intermediates and process for their preparation
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
ES2046193T3 (es) Un procedimiento para la preparacion de un compuesto de imidazolidinona.
ATE2622T1 (de) 2-niedrigalkyl-7-substituierte-2 oder 3-cephem-4- carbonsaeuren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES539123A0 (es) Un compuesto de 3-indolcarboxamida
EP0328203A3 (en) [5(6) (1H-azole-1-ylmethyl)benzimidazole] carbamates
EP0387070A3 (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
KR880002828A (ko) 디하이드로피리딘 유도체 및 이것의 약학적 조성말
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
CA2118425A1 (en) Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
MX9206930A (es) Nuevos compuestos
KR950032146A (ko) 트리아졸 화합물 및 이의 제조방법 및 용도
GB1497729A (en) Benzenesulphonyl ureas and process for their manufacture
FI833369A0 (fi) -aryl- -pyridylalkansyraderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutisk komposition

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid